← Who reports today · Health Care
DGX · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Quest Diagnostics' revenues rose 10.2% to $3.04B and net income attributable to Quest grew 13.5% to $320M, lifting diluted EPS 15.0% to $2.84.
Net income attributable to Quest Diagnostics
$320M
up 13.5% y/y
Net revenues
$3,043M
up 10.2% y/y
Operating income
$459M
up 4.8% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net revenues | $3,043 · +10.2% |
| Cost of services | $2,016 · +10.9% |
| Selling, general and administrative | $529 · +8.8% |
| Amortization of intangible assets | $38 · −2.6% |
| Other operating expense (income), net | $1 · vs −$20 |
| Operating income | $459 · +4.8% · 15.1% margin |
| Interest expense, net | $63 · −6.0% |
| Other income, net | $16 · +23.1% |
| Income before income taxes and equity in earnings of equity method investees | $412 · +7.3% |
| Income tax expense | $88 · −9.3% · 21.4% effective rate |
| Equity in earnings of equity method investees, net of taxes | $10 · +11.1% |
| Less: Net income attributable to noncontrolling interests | $14 · +0.0% |
| Net income attributable to Quest Diagnostics | $320 · +13.5% · $2.84/sh · 10.5% margin |
Verdict: Quest Diagnostics' revenues rose 10.2% to $3.04B and net income attributable to Quest grew 13.5% to $320M, lifting diluted EPS 15.0% to $2.84.
Full year 2026 revenues are now expected between $11.95 billion and $12.05 billion, and reported diluted EPS between $9.97 and $10.17.
Source and notation
Source: DGX press release, 8-K EX-99.1 of 07/23/2026 (SEC EDGAR).
Open as an image: DGX, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “DGX Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/dgx/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/dgx/q2-2026"><img src="https://whoreportstoday.com/t/dgx/q2-2026/sankey.png" alt="DGX Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/dgx/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/dgx/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/dgx/q2-2026">DGX Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Organic revenue grew 10.0%, and adjusted diluted EPS of $3.12 was up 19.1%.
- Operating income was $459M (+4.8% y/y), an operating margin of 15.1% vs 15.9% a year ago.
- Income tax of $88.0M implies an effective rate of 21.4% vs 25.3% a year ago.
- Diluted EPS was $2.84 vs $2.47 a year ago (+15.0%), while net income changed +13.5%.
What distorts the picture in this report and what to watch beyond the headlines.
DGX — a diagnostic testing company whose laboratories run clinical tests for physicians, hospitals, employers, health plans and patients and turn the results into diagnostic insights.
Its only reportable segment is Diagnostic Information Services, which provided more than 95% of 2025 revenue; risk assessment services for insurers and healthcare IT are reported as other operating segments. · Source: annual report (Form 10-K, SEC)
More reports: DHR · Q3 2026 · DVA · Q2 2026 · DXCM · Q2 2026 · ELV · Q3 2026 · EW · Q2 2026 · GEHC · Q3 2026 · GILD · Q2 2026 · HCA · Q3 2026 · HSIC · Q2 2026 · HUM · Q2 2026 · all reports